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Abstract
Background: The purpose of the present study is to compare finite size pencil beam (fsPB) and
Monte Carlo (MC) based optimization of lung intensity-modulated stereotactic radiotherapy (lung
IMSRT).
Materials and methods: A fsPB and a MC algorithm as implemented in a biological IMRT
planning system were validated by film measurements in a static lung phantom. Then, they were
applied for static lung IMSRT planning based on three different geometrical patient models (one
phase static CT, density overwrite one phase static CT, average CT) of the same patient. Both 6
and 15 MV beam energies were used. The resulting treatment plans were compared by how well
they fulfilled the prescribed optimization constraints both for the dose distributions calculated on
the static patient models and for the accumulated dose, recalculated with MC on each of 8 CTs of
a 4DCT set.
Results: In the phantom measurements, the MC dose engine showed discrepancies < 2%, while
the fsPB dose engine showed discrepancies of up to 8% in the presence of lateral electron
disequilibrium in the target. In the patient plan optimization, this translates into violations of organ
at risk constraints and unpredictable target doses for the fsPB optimized plans. For the 4D MC
recalculated dose distribution, MC optimized plans always underestimate the target doses, but the
organ at risk doses were comparable. The results depend on the static patient model, and the
smallest discrepancy was found for the MC optimized plan on the density overwrite one phase
static CT model.
Conclusions: It is feasible to employ the MC dose engine for optimization of lung IMSRT and the
plans are superior to fsPB. Use of static patient models introduces a bias in the MC dose
distribution compared to the 4D MC recalculated dose, but this bias is predictable and therefore
MC based optimization on static patient models is considered safe.
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Optimization of stereotactic lung intensity-modulated
radiotherapy (lung IMSRT) is challenging for two reasons.
First, because of uncertainties in dose calculation in the
presence of tissue interfaces (between lung and tumour),
and the commonly small fields. Second, because of the
uncertainties in dose calculation when optimizing on a
static patient model representing a moving target.
Although it has been well documented that conventional
(Pencil beam (PB), superposition/convolution) algo-
rithms fail to some degree when calculating dose to lung
[1-12], most treatment planning systems (TPSs) use these
algorithms both for optimization of lung IMSRT and for
final dose calculation, and MC only as a benchmarking
tool. Fraass et al [13] have stated that the use of MC dose
calculation algorithms for clinical planning improves the
dose accuracy in heterogeneous regions of lung and bony
anatomy, in particular when applying very small field
sizes which exhibit lateral electron disequilibrium effects.
Ideally, a TPS comprises a MC dose engine, since an inac-
curate dose algorithm will not only introduce dose errors,
but will also lead to wrongly optimized treatment plans.
The main argument for conventional algorithms has been
that the MC dose calculation algorithms are too slow,
especially for use in optimization of IMSRT [14]. How-
ever, with the computational power offered by modern
computers combined with an efficient MC system
[15,16], it should be feasible to use MC not only for recal-
culation of IMSRT treatment plans but also for optimiza-
tion itself. The biological IMRT MC-TPS HYPERION[17,18]
has been used clinically since 2002. The current version
allows for optimization based on both fsPB and MC. In
case of MC, it uses a Virtual Source Model (VSM) of the
accelerator head [15,16] together with the XVMC dose
engine for simulation in the patient [19].
In this study, we first compare our conventional fsPB and
MC algorithms to measurements in a lung phantom in
order to benchmark their overall accuracy. Then, we apply
both algorithms in optimization of lung IMSRT to inves-
tigate if direct optimization with MC can provide an
advantage over optimization with a conventional algo-
rithm and recalculation with MC.
The comparison of MC with conventional algorithms is
not independent of the patient model. Commonly, lung
IMSRT is performed on a static model of the moving target
and different approaches are used to represent the distri-
bution of densities within the Planning Target Volume
(PTV). In this study, we therefore also investigate the
influence of various patient models of the lung patient
geometry on the results of optimization and compare
these results to the real 4D accumulated dose, recalculated
with MC on each of 8 computer tomography scans (CTs)
representing 8 breathing phases [20].
Materials and methods
Verification of the MC and fsPB dose algorithms in a lung 
phantom
The MC and fsPB algorithms investigated in this study
have been presented in detail elsewhere (see [19,16] and
[21,22], respectively). Both algorithms calculate dose-to-
tissue, since the fsPB is commissioned based on the result
of simulation with the MC algorithm.
The lung phantom
We have used a phantom which models a small tumour
surrounded by lung tissue (Figure 1) to represent a typical
stereotactic lung case. Three plastic spheres representing
tumours of 2.7, 4.2 and 5.0 cm diameter were used. These
were inserted (one at the time) into the geometrical center
of a cork cube which mimicked the heterogeneous density
and composition of lung tissue. A slit in the cork and
through the tumour allowed for a film to be inserted into
the central plane of the phantom as shown in Figure 1. A
CT scan with a slice thickness of 2 mm was acquired of the
lung phantom (without film) for each tumour size and
used for dose calculation.
The lung phantom dose distribution calculation, measurements and 
2D dose comparisons
For each tumour size, a conformal plan consisting of one
vertical beam was created using 6 MV and 15 MV nominal
beam energies, and the dose delivered to the phantom
was calculated both with MC and fsPB. The maximum
dose in the tumour was below 1 Gy to avoid saturation of
the radiographic films.
A fine dose grid of 1 mm3 was used and the statistical
uncertainty of the MC simulations was set to 0.5%. The
presence of the dosimetric film was taken into account in
the dose calculations by introducing a 1 mm thick layer
filled with a density of ρ = 1.1  at the position of the
film in the CT scan of the lung phantom (as the CT acqui-
sition was made without the film).
Radiographic Kodak X-Omat V films were used for the
measurements. These were cut to fit the dimensions of the
phantom and placed into the central plane of the cork
cube between the hemispheres of the tumour perpendic-
ular to the beam direction (Figure 1). The cork cube was
then tightly fixed to the container and the phantom was
positioned with the help of the positioning markers. An
uncertainty in the position of the film plane of up to 2
degrees relatively to the beam direction was impossible to
avoid because of how the slit in the cork cube was cut (Fig-
g
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Radiation Oncology 2009, 4:64 http://www.ro-journal.com/content/4/1/64ure 1). An Elekta Synergy S accelerator was used to irradi-
ate the phantoms. All films were developed at the same
time and scanned with a Radlink LaserPro 16 scanner. The
optical densities of the films were converted to absolute
dose by using a calibration curve created for solid water.
The MC and fsPB dose distributions were compared to the
2D film measurements by using the γ-index method [23],
with an acceptance criteria of 3% dose difference and 3
mm distance-to-agreement (3%/3 mm). Also the tighter
2%/2 mm criteria was investigated. The artefacts from the
positioning markers of the phantom were excluded from
the analysis and no attempt was made to correct for the
slight uncertainty in the positioning of the film. The in-
plane and cross-plane profiles through the isocentre
where extracted from the 2D film measurements and
compared to the MC and fsPB dose distributions. Addi-
tionally, depth dose curves were compared between MC
and fsPB. The depth dose curves were not measured due
to unprecise alignment and a relatively high density con-
tribution of the film when its plane is located along the
beam direction.
The treatment planning optimization tool
An in-house developed optimization tool, HYPERION[18],
was used for treatment planning of lung IMSRT in this
study. The optimization process in HYPERION works by
constrained optimization whereby the tumour cell survival
is minimized while side effects to the relevant organs at
risk are constrained to the maximum tolerable. Details
about the optimization process and the HYPERION cost
functions can be found in [24,25]. The cost functions used
for the purpose of this study were:
1. a poisson cell-kill EUD (equivalent uniform dose)
model to maximize tumour control [26],
2. a parallel complication model to limit the damage to
the lungs by constraining the relative fraction of the
organ which can be damaged [24,25],
3. and a maximum overdosage constraint to avoid target
hotspots and to control maximum organ at risk doses
in terms of the root mean square (rms) overdosage
above a given threshold dose.
Plan optimization is a two-stage process. In stage I, the
fsPB computes dose distributions for a large number of
beamlets that constitute the fluence profiles. Then, the
weights of these beamlets are optimized to yield the ideal-
ized fluence profiles. Stage II starts with an initial segmen-
tation of the fluence profiles into a sequence of
deliverable MLC segments. Here, the segment doses can
either be obtained from a concatenation of their beamlet
doses or by a MC calculation. The weights and shapes of
these sequences are optimized as described in [27]. In case
a segment changes shape, the MC calculation is re-run. An
approach via MC-calculated beamlets meets two obsta-
cles: firstly, for a given incident history density, the point-
wise dose uncertainty of a beamlet is greater because the
dose is smeared out over a greater volume, which in turn
causes instabilities in the optimization. Secondly, by def-
inition a beamlet dose cannot include MLC effects which
requires a re-computation of the full segment doses in
stage II anyway and leads to wrong (usually too steep)
field penumbra in stage I.
Optimization of lung IMSRT plans with MC and PB
Patient data and models
One example patient which had previously been treated
with lung IMSRT at the University Hospital of Tübingen
was used in the study. The patient had a tumour with a
diameter of 2.4 cm which was located posteriorly in the
lower right lung. The breathing excursion was 2.9 cm
mainly in the cranio-cadual direction. A respiratory-corre-
lated CT (RCCT) dataset was acquired with a Siemens Sen-
sation Open scanner reconstructed with 1 × 1 × 3 mm3
voxel size. The CT dataset was grouped into eight CT sets
(0/25/50/75% inhale and 100/75/50/25% exhale), where
the 0% inhale CT was used as the planning geometry (the
static exhale (planning) CT). Contours of the clinical tar-
Lung phantomFigure 1
Lung phantom. Cross sections through the CT scan of the 
lung phantom which consisted of a low density cork cube 
surrounding a homogeneous plastic sphere of variable diame-
ter (here: 4.2 cm). The cork cube densities ranged from ρmin 
= 0.001 to ρmax = 1.09  with an average density of ρmean 
= 0.12 , while the plastic sphere had a density of ρ = 1.1 
. A film could be positioned through the phantom as 
marked with a dashed line in A and B. The cork cube, plastic 
sphere and film were fixed relatively to the high density posi-
tioning markers (indicated by arrows on A) on the surface of 
the plastic container by a plastic plate and four plastic screws 
as shown in B.
BA
g
cm3
g
cm3
g
cm3Page 3 of 13
(page number not for citation purposes)
Radiation Oncology 2009, 4:64 http://www.ro-journal.com/content/4/1/64get volumes (CTVs) from all breathing phases as well as of
the organs at risk (OARs) were defined and approved by a
radiologist. The planning target volume (PTV) was
defined as the internal target volume (ITV), i.e. the union
of the CTVs from all breathing phases, expanded by 2 mm
in order to account for setup uncertainties. This resulted in
a PTV of 47.1 cm3, around three times larger than the clin-
ical target volume (CTV).
Treatment planning was based on three different patient
models accounting for spatial and temporal variations in
density within the PTV:
1. one phase static CT : this model uses the PTV and the
exhale planning CT without any attempt to correct for
density variations,
2. minimum density overwrite, one phase static CT : in this
model, a density less then 0.4  (an empirical value
to avoid erratic fluence modulation caused by density-
related underdosage in the target volume) was raised
to this value within the PTV on the planning CT to
mimic the effective density during free breathing irra-
diation,
3. average CT: this model uses the PTV and a superpo-
sition of all RCCTs, such that each voxel has a density
equal to the weighted average of the Hounsfield values
from all breathing phases.
Static lung IMSRT planning
For all three patient models IMSRT plans for both 6 and
15 MV beam energies were optimized with both the fsPB
and the MC algorithm. The same constraints and a beam
arrangement consisting of eleven beams (with gantry
angles of 20, 155, 175, 195, 215, 235, 270, 295, 310, 325
and 345), was used in each case. The PTV was prescribed
to receive 55 Gy (EUD) in n = 10 fractions and a maxi-
mum overdosage constraint of 2 Gy rms above the pre-
scribed dose was applied to avoid hotspots within the PTV
(see table 1). Sparing of the contralateral and ipsilateral
lung was obtained by constraining the mean dose to 2 and
9 Gy, respectively, and by constraining the mean damage
to a relative volume of maximum 8% and 21%, respec-
tively, estimated with the parallel complication model
defined by do = 20 Gy and k = 3 [24,25]. In addition, max-
imum overdosage constraints of 9 Gy and 21 Gy were
applied to the spinal cord and unspecified normal tissue
within the skin contour.
A beamlet size of 4 × 2 mm2 was used and segments
smaller than 0.64 cm2 were not allowed. We used a 2.5 ×
2.5 × 2.5 mm3 dose calculation grid size and a 3% statisti-
cal uncertainty per MLC segment for the MC calculation.
After optimization, the fsPB plans were recalculated in the
static geometries with the MC dose engine. Additionally,
all plans were recalculated by 4DMC.
For 4D MC plan calculation (4DMC), the dose was com-
puted in each of the eight static geometries of the RCCT
dataset. These MC doses per instance were weighted
according to their share of the breathing cycle and accu-
mulated in a common reference geometry (here, the
exhale planning CT) by dose warping derived from
deformable registration. Details of the 4DMC recalcula-
tion method are described in details in [20]. It is impor-
tant to notice that the PTV encloses a volume where the
tumor can be found with certain probability which
depends on the breathing pattern. Therefore, it is not pos-
sible to evaluate the real dose to the CTV without employ-
ing the 4DMC recalculation where the accumulated dose
in the CTV is calculated. In the following, we use a com-
mon term - target volume, which denotes the PTV for static
planning and the CTV for 4DMC recalculation, respec-
tively.
Results
Experimental verification of MC and fsPB dose engines
The 2D γ comparison between the measured and calcu-
lated dose distributions is shown in Figure 2 and Table 2
for 6 MV and 15 MV beam energies. Overall, a good agree-
ment was found between MC dose calculation and film
measurements, with more than 97% of the points fulfill-
ing the 3%/3 mm acceptance criteria and 84-97% of the
points fulfilling the 2%/2 mm criteria. For the fsPB algo-
rithm, the agreement was worse both inside and outside
the tumour. Of all points, 45-81% fulfilled the 3%/3 mm
acceptance criteria and 25-52% of the points fulfilled the
2%/2 mm criteria. The in-plane and cross-plane profiles
(Figure 3) show that the fsPB algorithm underestimates
the dose in the target by up to 8%, and produces a too
steep penumbra compared to MC and film. The depth
dose profile comparison (Figure 4) further shows that MC
and fsPB disagree by up to 20% in lung tissue for 15 MV
and by up to 15% for 6 MV.
Static IMSRT dose distributions
An example of the resulting dose distribution from opti-
mization with fsPB and MC is shown in Figure 5, and the
prescribed and resulting isoeffects/EUDs for all plans are
listed in Table 1. All plans were very close to formally ful-
filling the prescribed OAR constraints. The plans opti-
mized with fsPB were also close to fulfilling the prescribed
target-EUD for all patient models, while the MC opti-
mized plans resulted in a lower target-EUD than pre-
scribed in all patient models.
The MC recalculation on the static patient models of the
fsPB optimized plans shows that most of the prescribed
g
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found that the fsPB dose calculation algorithm underesti-
mated the target-EUD in case of 6 MV and overestimated
the target-EUD in case of 15 MV for all patient models.
The 4DMC recalculation showed that the MC calculated
dose on the static patient models actually underestimated
the target-EUD for all patient models and for both 6 and
15 MV, while OAR isoeffects/EUDs were comparable
(Table 1). The largest difference between the target-EUD
calculated with the static patient model compared to 4D
MC was found for the one phase static CT patient model
and the smallest difference was found for the minimum
density overwrite one phase static CT model, independent of
beam energy (Figure 6). The 4DMC recalculation of the
fsPB optimized plans confirmed that most of the OAR
constraints were violated and that the fsPB dose calcula-
tion algorithm underestimated the target-EUD in case of 6
MV and overestimated the target-EUD in case of 15 MV for
all patient models for this specific patient. Figure 7 shows
DVHs of the ipsilateral lung. For all patient models, PB-
static plans consequently underestimated dose relatively
to the 4DMC accumulated dose while MC-static plans
agree very well with the 4DMC accumulated dose. Small
discrepancies can be noticed for MC treatment plans in
lung volume close to the tumor where the MC-static plans
Table 1: Prescribed and resulting isoeffects/EUDs for all patient models plans optimized with fsPB and MC and recalculated with 
4DMC; the recalculated MC dose on the static patient models of the fsPB optimized plans are shown in brackets.
6 MV 15 MV
Quantity type Prescr. PB 4D MC 4D PB 4D MC 4D
model 1, one phase static CT
target* poisson EUD 55 Gy 54.25 (57.94) 58.86 53.3 57.35 55.32 (52.77) 55.47 52.09 58.82
target* rms overdosage 2 Gy 1.99 (4.17) 4.48 1.53 3.39 2.02 (0.66) 1.95 1.97 5.83
lung R, mean dose 9 Gy 8.39 (10.58) 10.81 9.1 9.32 8.46 (10.31) 10.47 9 9.26
lung R, mean damage 21% 20.49 (24.48) 24.93 21.68 22.05 20.71 (23.9) 24.21 21.17 21.6
skin, rms overdosage 0.24 Gy 0.23 (0.61) 0.59 0.24 0.24 0.24 (0.52) 0.52 0.24 0.24
model 2, minimum density overwrite one phase static CT
target* poisson EUD 55 Gy 56.47 (57.23) 57.53 54.98 56.2 55.95 (53.68) 54.37 52.47 56.02
target* rms overdosage 2 Gy 2.05 (3.23) 2.83 2.02 1.8 2.02 (0.96) 0.6 2.07 2.6
lung R, mean dose 9 Gy 8.13 (9.63) 9.84 8.91 9.13 8.34 (9.96) 10.06 8.71 8.88
lung R, mean damage 21% 19.9 (22.57) 23.03 21.25 21.66 20.43 (23.14) 23.38 20.59 20.88
skin, rms overdosage 0.24 Gy 0.23 (0.48) 0.48 0.24 0.23 0.24 (0.48) 0.48 0.24 0.23
model 3, average CT
target* poisson EUD 55 Gy 55.03 (57.53) 57.46 52.63 55.88 55.32 (52.57) 55.01 51.85 58.49
target* rms overdosage 2 Gy 1.99 (3.71) 3.09 1.12 1.66 2 (0.52) 1.25 2.01 4.63
lung R, mean dose 9 Gy 8.43 (10.41) 10.64 9.12 9.33 8.49 (10.3) 10.49 9.04 9.3
lung R, mean damage 21% 20.56 (24.14) 24.61 21.74 22.13 20.72 (23.85) 24.23 21.21 21.66
skin, rms overdosage 0.24 Gy 0.24 (0.61) 0.6 0.24 0.23 0.24 (0.53) 0.53 0.24 0.23
target* - the target dose is calculated in the PTV for static planning and the CTV for 4DMC recalculation, respectively.
Table 2: Agreement between the 2D dose distributions as measured with film and calculated with MC and fsPB for the 3%/3 mm and 
2%/2 mm γ acceptance criteria; the acceptance (in %) is listed for the whole region (all), the tumour region (tumour) and the region 
outside the tumour (lung) and for all tumour sizes.
MC 3%/3 mm fsPB 3%/3 mm MC 2%/2 mm fsPB 2%/2 mm
Tumour diameter [cm] all tumour lung all tumour lung all tumour lung all taret lung
6 MV
2.7 99.6 99.6 99.6 71.8 67.4 72.2 97.3 97.1 97.3 43.3 43.1 43.3
4.2 99.3 99.0 99.4 49.4 31.2 53.1 96.0 92.0 96.8 28.5 23.7 29.5
5.0 97.0 97.2 97.0 46.6 31.3 51.4 89.4 94.4 87.8 30.5 21.2 33.4
15 MV
2.7 99.9 99.6 99.9 81.4 60.6 83.0 97.4 96.8 97.4 52.2 41.4 53.0
4.2 97.8 99.6 97.4 51.2 42.4 53.0 84.0 96.7 81.4 25.3 27.7 24.8
5.0 98.3 98.9 98.1 45.4 37.7 47.8 89.8 93.9 88.5 26.6 22.8 27.8Page 5 of 13
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Verification of dose engines - γ-plotsFigure 2
Verification of dose engines - γ-plots. γ-plots of the dose distributions measured with film and calculated with MC and fsPB 
for all tumour sizes for 6 MV (upper set) and 15 MV (lower set). The acceptance criteria for the γ comparisons was set to 3%/
3 mm. The tumour outlines are marked by black circles.
Radiation Oncology 2009, 4:64 http://www.ro-journal.com/content/4/1/64
Page 7 of 13
(page number not for citation purposes)
Verification of dose engines - dose profilesFigure 3
Verification of dose engines - dose profiles. 6 MV (upper plots) and 15 MV (lower plots) in-plane (Y) and cross-plane (X) 
dose profiles as measured with film (solid) and calculated with both MC (dotted) and fsPB (dashed) algorithms for tumour I-III.
Radiation Oncology 2009, 4:64 http://www.ro-journal.com/content/4/1/64slightly overestimated the lung dose which is related to
smearing out high dose isolines to larger volume around
the target for the static patient models. A performance test
of the PB and MC planning showed that the PB planning
(PB beamlet allocation, PB beamlet optimization, PB dose
segment weight and shape optimization and final PB dose
calculation) takes less than 30 min while the MC planning
(PB beamlet allocation, PB beamlet optimization, MC
dose segment weight and shape optimization and final
MC dose calculation) takes from 1 h to 1.5 h depending
on the difficulty of converging to the plan constraints and
the number of segments in the final plan.
Discussion
In this study we have shown how dose calculation of
small fields in the presence of tissue heterogeneities and
static modelling of a moving target influence fsPB and MC
dose calculation and optimization for lung IMSRT. The
results of the lung IMSRT planning are presented for one
extreme case (small tumor, large movements, density
inhomogeneities) in order to emphasize possible dose
calculation and patient model uncertainties and less
extreme cases will produce smaller problems.
While the MC dose calculation performed well for a static
lung phantom, the fsPB algorithm always underestimated
the target dose compared to film measurements. This con-
firms what has been found by others for various superpo-
sition/convolution and collapsed cone algorithms
[10,12,28,8,3,5,29]. The MC can safely be regarded as the
superior algorithm for dose calculation on a static geome-
try.
When looking at real patient data of lung IMSRT, the pic-
ture gets more complicated and it is difficult to interpret
the results from fsPB planning. Vanderstraeten et al. [29]
investigated dose calculation with various commercially
available conventional dose engines, and showed overes-
timation or underestimation of the target dose when com-
paring to the MC calculated dose, depending on the
algorithm. Our results showed that our fsPB algorithm
both underestimated and overestimated the target-EUD
depending on the energy (6 or 15 MV). This is related to
uncertainties in penumbra widening factors (especially
parameter fu1(ρ)) of the fit functions implemented in the
fsPB for low densities (Figure 4, Jeleń et al [22]). The dose
to the ipsilateral lung calculated by the fsPB was underes-
timated for all static plans while MC static plans agreed
Verification of dose engines - depth dose curvesFigure 4
Verification of dose engines - depth dose curves. 6 MV (upper row) and 15 MV (lower row) depth dose profiles (Z) cal-
culated with MC (solid) and fsPB (dashed) algorithms for tumour I-III.Page 8 of 13
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Radiation Oncology 2009, 4:64 http://www.ro-journal.com/content/4/1/64very well with the 4DMC recalculations. Thus, for this
patient example lung IMSRT treatment planning with the
fsPB results in higher complication probability then MC-
based planning.
In addition to an unpredictable target-EUD, optimization
with fsPB led to violation of most OAR constraints for
both low and high energy photon beams when compared
to MC recalculated dose on both the static and 4D patient
models. This means that optimization with fsPB and
recalculation with MC is impractical, because the violated
OAR constraints would have to be readjusted and the
whole optimization procedure rerun. Bearing this in
mind, optimization with fsPB and recalculation with MC
may not necessarily be more efficient than MC based opti-
mization which needed less than 1.5 hours in our case.
Although MC is superior to fsPB on a static geometry, the
real accumulated dose to the patient is influenced by the
breathing motion during delivery. In our study, the 4D
MC recalculations of the MC optimized treatment plans
showed that the target doses calculated on the static
patient models were always lower than the 4D accumu-
lated target dose.
The differences between static and 4D recalculated MC
dose depended on the patient model. The largest differ-
ence, as expected, was found for the one phase static CT
model, where a large part of the target was occupied by
low density lung tissue to where the optimizer tried to
deliver a higher fluence in order to achieve a homogene-
ous target dose. The minimum density overwrite one phase
static CT model worked well for our patient, especially for
the 6 MV plan. The advantage of this patient model is that
the optimizer is not miss-leaded by low densities in the
target. In contrast, the average CT model still contains a
significant fraction of low density lung tissue (like the one
phase static CT model) to where the optimizer also tries to
boost the dose but which is rarely visited by the tumor.
For the fsPB optimized plans, 4D MC recalculation dis-
played a complex picture where dose calculation uncer-
tainties and geometrical uncertainties either added up or
Dose distribution isodosesFigure 5
Dose distribution isodoses. Example of the resulting dose distributions from optimization with fsPB and MC with 6 MV 
beam energy and using the average CT patient model (a). The same plans recalculated with 4DMC (b).
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Target dose distribution DVHsFigure 6
Target dose distribution DVHs. Target (PTV) DVHs of the PB and MC static plans (solid) and their 4DMC calculation 
(CTV accumulated dose DVHs) (dashed). Calculated for 6 MV (left column) and 15 MV (right column) for the one phase static 
CT (a, b); the minimum density overwrite one phase static CT (c, d) and the average CT (e, f) patient models.
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Ipsilateral lung dose distribution DVHsFigur  7
Ipsilateral lung dose distribution DVHs. Ipsilateral lung DVHs of the PB and MC static plans (solid) and their 4DMC calcu-
lation (accumulated dose DVHs) (dashed). Calculated for 6 MV (left column) and 15 MV (right column) for the one phase static 
CT (a, b); the minimum density overwrite one phase static CT (c, d) and the average CT (e, f) patient models.
Radiation Oncology 2009, 4:64 http://www.ro-journal.com/content/4/1/64cancelled out. Because only geometrical uncertainties
were present with the MC optimized plans, these were
more predictable. Although always underestimating the
target dose compared to 4D MC, the MC optimized plans
showed only small deviations in the OAR isoeffects/
EUDs, especially for relatively static organs. The 4DMC
dose were higher because the dose "follows" the higher
density of the tumor during breathing. We therefore con-
sider MC based optimization on static patient models to
be a safe method for lung IMSRT planning for the mini-
mum density or average CT models tested in this study.
4D MC optimization was not considered in the present
paper. It eliminates the uncertainties in the geometrical
model and provides the optimal dose for free breathing
IMSRT treatment with a negligible increase of optimiza-
tion and calculation time at the price of a greater depend-
ency on the consistency between predicted and realized
patient breathing motion [20].
Conclusion
The MC dose engine was superior to fsPB in presence of
lateral electron disequilibrium on static geometries. With
an efficient MC system, MC based optimization of lung
IMSRT is feasible, also given clinical time constraints. MC
dose optimization on static patient models always under-
estimated the CTV dose compared to 4DMC recalcula-
tions, but OAR differences were very small. Therefore, MC
optimization of lung IMSRT using a static patient model
is recommended.
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